<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02912455</url>
  </required_header>
  <id_info>
    <org_study_id>16-574</org_study_id>
    <nct_id>NCT02912455</nct_id>
  </id_info>
  <brief_title>CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes</brief_title>
  <official_title>Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized clinical trial for patients with recurrent type 2 diabetes
      post-gastric bypass surgery that will compare a 6 month course of canagliflozin monotherapy
      vs. placebo on clinical outcomes of type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following consent and a screening visit to assess eligibility and clinical status (i.e.
      historical, physical and biochemical parameters including glycemic control and a pregnancy
      test in females), a baseline visit with diabetes educator will take place to provide standard
      diabetes education, nutrition and exercise prescription.

      Nutritional assessment for vitamin/mineral deficiency will be performed per clinical care
      guidelines at the screening visit. Subjects will be asked to take nutritional supplements
      (i.e. vitamins and minerals) per current clinical guidelines for post-bariatric patients.
      Stable doses of supplements will be established for at least 2 weeks prior to randomization.
      Thirty-six subjects with recurrent diabetes that are na√Øve to hypoglycemic agents with HbA1c
      greater than or equal to 6.5% and less than 10% will be randomly assigned to a six month
      course of a) canagliflozin 100mg for 2 weeks titrated up to 300 mg daily (N = 24) vs. placebo
      (n= 12) at the randomization. Patients taking an anti-diabetic medication will be asked to
      wash out for 8 weeks prior to the randomization visit. At randomization, biochemical
      assessment of glycemic parameters (fasting glucose, HbA1c), lipid panel, complete metabolic
      panel, uric acid, leptin, total and HMW adiponectin, C-reactive protein and urine for
      albumin/creatinine ratio will be performed. Dual-energy x-ray absorptiometry (DXA) scan will
      be performed for body fat composition.

      Following randomization, subjects will be clinically evaluated at three office visits at 6
      weeks, 3 and 6 months by PI and/or the research staff. The primary outcome measures at 6
      months post-randomization include HbA1c followed by the change in HbA1c from randomization.
      Secondary measures include fasting glucose, BMI, change in body weight, blood pressure, lipid
      profile. Symptomatic hypoglycemia (blood glucose &lt; 70) and drug related side effects (i.e.
      mycotic genital infections, urinary tract infection) will be monitored with adverse event
      reporting. Metabolic testing in all subjects at randomization and at 6 months will include a
      DXA scan for body fat composition and blood for leptin and adiponectin levels.

      Rescue glucose lowering therapy will be provided for the control group for blood glucose &gt;250
      mg/dl. If chronic uncontrolled hyperglycemia (HbA1c &gt;10%) occurs then basal bolus insulin
      will be implemented.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to difficulty with reaching enrollment goals
  </why_stopped>
  <start_date type="Actual">January 5, 2017</start_date>
  <completion_date type="Actual">July 19, 2018</completion_date>
  <primary_completion_date type="Actual">July 19, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change in Hemoglobin A1c From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery</measure>
    <time_frame>6 months</time_frame>
    <description>Actual change at six months versus baseline in hemoglobin A1c value (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose From Randomization</measure>
    <time_frame>6 months</time_frame>
    <description>The change in fasting glucose from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Body Weight From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</measure>
    <time_frame>6 months</time_frame>
    <description>Change in body weight at six months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Total Cholesterol From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Diastolic Blood Pressure From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery</measure>
    <time_frame>6 months</time_frame>
    <description>Change in diastolic blood pressure at six months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Adiponectin Levels From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</measure>
    <time_frame>6 months</time_frame>
    <description>Change in adiponectin levels at 6 months compared to randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Leptin Levels From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</measure>
    <time_frame>6 months</time_frame>
    <description>Change in leptin levels at 6 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in C-reactive Protein Levels From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</measure>
    <time_frame>6 months</time_frame>
    <description>Change in CRP levels at 6 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Symptomatic Hypoglycemia Episodes From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants who reported hypoglycemia from each group (at a frequency of 1 episode)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Body Fat From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</measure>
    <time_frame>6 months</time_frame>
    <description>Change in percent body fat as measured by DEXA scan at 6 months compared to randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Systolic Blood Pressure From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery</measure>
    <time_frame>6 months</time_frame>
    <description>Change in systolic blood pressure at 6 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Lean Mass</measure>
    <time_frame>6 months</time_frame>
    <description>Change in percentage of lean body mass as measured by DEXA scan at 6 months compared to randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Truncal Fat</measure>
    <time_frame>6 months</time_frame>
    <description>Change in percentage of truncal fat as measured by DEXA scan at 6 months compared to randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Android Fat</measure>
    <time_frame>6 months</time_frame>
    <description>Change in percentage of android fat as measured by DEXA scan at 6 months compared to randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Gynoid Fat</measure>
    <time_frame>6 months</time_frame>
    <description>Change in percentage of gynoid fat as measured by DEXA scan at 6 months compared to randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spine Bone Mineral Density</measure>
    <time_frame>6 months</time_frame>
    <description>Change in spine bone marrow density as measured by DEXA scan at 6 months compared to randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leg Bone Mineral Density</measure>
    <time_frame>6 months</time_frame>
    <description>Change in leg bone marrow density as measured by DEXA scan at 6 months compared to randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Study Drug (canagliflozin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>canagliflozin</intervention_name>
    <description>encapsulated (gelatin capsule).</description>
    <arm_group_label>Study Drug (canagliflozin)</arm_group_label>
    <other_name>Invokana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for canagliflozin)</intervention_name>
    <description>encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post Roux-n-Y gastric bypass (RYGB) surgery and sleeve gastrectomy (SG) patients who
             underwent surgery &gt;1 and &lt;15 years ago in the Cleveland surrounding area

          -  Age 20-75 years of age

          -  Type II Diabetes Mellitus (D2M) diagnosis (history, medication usage, biochemical
             criteria) prior to and after surgery; after surgery, defined by a single HbA1c of
             greater or equal to 6.5% at consent and screening.

          -  Metformin patients must have an HbA1c greater than or equal to 6.5% but less than or
             equal to 10% at randomization; for diet controlled patients (i.e. not on any T2D
             medication), HbA1c must be greater than or equal to 6.5% at randomization.

          -  Patient reporting of improvement in T2D status or objective improvements in T2D status
             at any time post-surgery.

          -  estimated glomerular filtration rate (eGFR) ‚â• 60mL/min prior to randomization

          -  Has the ability and willingness to provide informed consent.

          -  Is able to understand the options and to comply with the requirements of each program

          -  Female subject agrees to have a serum pregnancy test at screening. A negative serum
             pregnancy test result is required prior to randomization.

          -  Female patients must agree to use a reliable method of contraception for 6 months or
             duration of intervention

          -  Patients taking an anti-diabetic medication, except insulin, are eligible and must
             agree to washout for 8 weeks prior to the randomization visit.

        Exclusion Criteria:

          -  Type 1 diabetes indicated by history of diabetic ketoacidosis and lack of remission in
             response to bariatric surgery

          -  Other post bariatric procedures (banding, duodenal switch, biliopancreatic diversion)

          -  Current use of insulin.

          -  End organ diabetic complications (renal failure, cardiomyopathy, severe
             neuropathy/foot ulcers)

          -  Documented severe or unstable depression/anxiety or eating disorder that would not
             enable patient to adhere to anti-diabetic treatment

          -  Clinical contraindications to use canagliflozin, i.e., history of bladder cancer,
             Child-Pugh class C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sangeeta Kashyap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 24, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <results_first_submitted>November 12, 2019</results_first_submitted>
  <results_first_submitted_qc>June 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2020</results_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Sangeeta Kashyap</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Post-Bariatric Surgery</keyword>
  <keyword>hemoglobin A1c protein, human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02912455/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Drug (Canagliflozin)</title>
          <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 11).
canagliflozin: encapsulated (gelatin capsule).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =5).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Drug (Canagliflozin)</title>
          <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily.
canagliflozin: encapsulated (gelatin capsule).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Drug: Placebo (for canagliflozin)
encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="38" upper_limit="75"/>
                    <measurement group_id="B2" value="44.0" lower_limit="34.0" upper_limit="59.0"/>
                    <measurement group_id="B3" value="54.0" lower_limit="34.0" upper_limit="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" lower_limit="28.6" upper_limit="49.4"/>
                    <measurement group_id="B2" value="37.9" lower_limit="31.9" upper_limit="44.7"/>
                    <measurement group_id="B3" value="39.2" lower_limit="28.6" upper_limit="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (m)</title>
          <units>meters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" lower_limit="1.5" upper_limit="1.7"/>
                    <measurement group_id="B2" value="1.7" lower_limit="1.6" upper_limit="1.9"/>
                    <measurement group_id="B3" value="1.7" lower_limit="1.5" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.6" lower_limit="78.3" upper_limit="132.9"/>
                    <measurement group_id="B2" value="117.5" lower_limit="86.0" upper_limit="133.7"/>
                    <measurement group_id="B3" value="108.9" lower_limit="78.3" upper_limit="133.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (%)</title>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" lower_limit="6.5" upper_limit="8.3"/>
                    <measurement group_id="B2" value="8.2" lower_limit="6.9" upper_limit="10.0"/>
                    <measurement group_id="B3" value="7.4" lower_limit="6.5" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose (mg/dL)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163.0" lower_limit="105.0" upper_limit="204.0"/>
                    <measurement group_id="B2" value="164.0" lower_limit="116.0" upper_limit="239.0"/>
                    <measurement group_id="B3" value="163.5" lower_limit="105.0" upper_limit="239.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure (mm/Hg)</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.0" lower_limit="52.0" upper_limit="87.0"/>
                    <measurement group_id="B2" value="77.0" lower_limit="51.0" upper_limit="86.0"/>
                    <measurement group_id="B3" value="76.5" lower_limit="51.0" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure (mm/Hg)</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137.0" lower_limit="106.0" upper_limit="148.0"/>
                    <measurement group_id="B2" value="133.0" lower_limit="117.0" upper_limit="141.0"/>
                    <measurement group_id="B3" value="134.5" lower_limit="106.0" upper_limit="148.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Uric acid (mg/dL)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" lower_limit="2.9" upper_limit="7.9"/>
                    <measurement group_id="B2" value="3.9" lower_limit="3.3" upper_limit="5.1"/>
                    <measurement group_id="B3" value="4.3" lower_limit="2.9" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol (mg/dL)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160.0" lower_limit="112.0" upper_limit="257.0"/>
                    <measurement group_id="B2" value="167.0" lower_limit="135.0" upper_limit="202.0"/>
                    <measurement group_id="B3" value="162.0" lower_limit="112.0" upper_limit="257.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides (mg/dL)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130.0" lower_limit="59.0" upper_limit="224.0"/>
                    <measurement group_id="B2" value="107.0" lower_limit="62.0" upper_limit="121.0"/>
                    <measurement group_id="B3" value="109.5" lower_limit="59.0" upper_limit="224.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL (mg/dL)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.0" lower_limit="31.0" upper_limit="175.0"/>
                    <measurement group_id="B2" value="108.0" lower_limit="67.0" upper_limit="120.0"/>
                    <measurement group_id="B3" value="92.0" lower_limit="31.0" upper_limit="175.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL (mg/dL)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" lower_limit="28.0" upper_limit="81.0"/>
                    <measurement group_id="B2" value="51.0" lower_limit="29.0" upper_limit="60.0"/>
                    <measurement group_id="B3" value="49.0" lower_limit="28.0" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body fat %</title>
          <units>percentage of body fat</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" lower_limit="30.5" upper_limit="55.3"/>
                    <measurement group_id="B2" value="44.1" lower_limit="29.4" upper_limit="51.0"/>
                    <measurement group_id="B3" value="48.6" lower_limit="29.4" upper_limit="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lean mass %</title>
          <units>percentage of lean mass</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" lower_limit="44.7" upper_limit="69.5"/>
                    <measurement group_id="B2" value="55.9" lower_limit="49.0" upper_limit="70.6"/>
                    <measurement group_id="B3" value="51.5" lower_limit="44.7" upper_limit="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Truncal fat</title>
          <units>percentage of truncal fat</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" lower_limit="36.8" upper_limit="55.3"/>
                    <measurement group_id="B2" value="47.8" lower_limit="34.9" upper_limit="54.0"/>
                    <measurement group_id="B3" value="50.9" lower_limit="34.9" upper_limit="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Android fat</title>
          <units>percentage of android fat</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" lower_limit="41.1" upper_limit="58.6"/>
                    <measurement group_id="B2" value="51.3" lower_limit="38.0" upper_limit="56.3"/>
                    <measurement group_id="B3" value="53.9" lower_limit="38.0" upper_limit="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gynoid fat</title>
          <units>percentage of gynoid fat</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" lower_limit="27.5" upper_limit="55.3"/>
                    <measurement group_id="B2" value="47.3" lower_limit="30.1" upper_limit="55.6"/>
                    <measurement group_id="B3" value="47.7" lower_limit="27.5" upper_limit="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spine BMD</title>
          <units>g/cm^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.2" lower_limit="1.03" upper_limit="1.8"/>
                    <measurement group_id="B2" value="1.3" lower_limit="1.05" upper_limit="1.3"/>
                    <measurement group_id="B3" value="1.2" lower_limit="1.03" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Leg BMD</title>
          <units>g/cm^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.2" lower_limit="1.07" upper_limit="1.9"/>
                    <measurement group_id="B2" value="1.2" lower_limit="1.05" upper_limit="1.4"/>
                    <measurement group_id="B3" value="1.2" lower_limit="1.05" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HMW adiponectin</title>
          <units>ug/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" lower_limit="0.8" upper_limit="10"/>
                    <measurement group_id="B2" value="3.3" lower_limit="1.6" upper_limit="7"/>
                    <measurement group_id="B3" value="3.1" lower_limit="0.8" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adiponectin</title>
          <units>ug/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" lower_limit="1.5" upper_limit="17"/>
                    <measurement group_id="B2" value="5" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="B3" value="4.6" lower_limit="1.5" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Leptin</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" lower_limit="5.3" upper_limit="87"/>
                    <measurement group_id="B2" value="29" lower_limit="4.7" upper_limit="117"/>
                    <measurement group_id="B3" value="28.5" lower_limit="4.7" upper_limit="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CRP</title>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" lower_limit="1.00" upper_limit="44.5"/>
                    <measurement group_id="B2" value="0.45" lower_limit="0.20" upper_limit="3.8"/>
                    <measurement group_id="B3" value="3.7" lower_limit="0.20" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change in Hemoglobin A1c From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery</title>
        <description>Actual change at six months versus baseline in hemoglobin A1c value (%)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Hemoglobin A1c From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery</title>
          <description>Actual change at six months versus baseline in hemoglobin A1c value (%)</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" lower_limit="-0.72" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.11" lower_limit="-0.71" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose From Randomization</title>
        <description>The change in fasting glucose from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose From Randomization</title>
          <description>The change in fasting glucose from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.90" lower_limit="-56.02" upper_limit="-9.79"/>
                    <measurement group_id="O2" value="-44.61" lower_limit="-102.39" upper_limit="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Body Weight From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
        <description>Change in body weight at six months compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Body Weight From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
          <description>Change in body weight at six months compared to baseline</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.77" lower_limit="-6.33" upper_limit="-1.22"/>
                    <measurement group_id="O2" value="6.33" lower_limit="-1.50" upper_limit="14.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Total Cholesterol From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Total Cholesterol From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" lower_limit="-26.59" upper_limit="24.85"/>
                    <measurement group_id="O2" value="3.69" lower_limit="-37.53" upper_limit="44.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Diastolic Blood Pressure From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery</title>
        <description>Change in diastolic blood pressure at six months compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Diastolic Blood Pressure From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery</title>
          <description>Change in diastolic blood pressure at six months compared to baseline</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" lower_limit="-6.62" upper_limit="4.26"/>
                    <measurement group_id="O2" value="2.95" lower_limit="-13.69" upper_limit="19.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Adiponectin Levels From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
        <description>Change in adiponectin levels at 6 months compared to randomization</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Adiponectin Levels From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
          <description>Change in adiponectin levels at 6 months compared to randomization</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="-2.2" upper_limit="5.7"/>
                    <measurement group_id="O2" value="-3.4" lower_limit="-9.3" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Leptin Levels From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
        <description>Change in leptin levels at 6 months compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Leptin Levels From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
          <description>Change in leptin levels at 6 months compared to baseline</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" lower_limit="-35.1" upper_limit="18.9"/>
                    <measurement group_id="O2" value="-11" lower_limit="-93.1" upper_limit="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in C-reactive Protein Levels From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
        <description>Change in CRP levels at 6 months compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in C-reactive Protein Levels From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
          <description>Change in CRP levels at 6 months compared to baseline</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.35" lower_limit="-13.81" upper_limit="3.12"/>
                    <measurement group_id="O2" value="3.34" lower_limit="-0.76" upper_limit="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Symptomatic Hypoglycemia Episodes From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
        <description>Number of participants who reported hypoglycemia from each group (at a frequency of 1 episode)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Symptomatic Hypoglycemia Episodes From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
          <description>Number of participants who reported hypoglycemia from each group (at a frequency of 1 episode)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Body Fat From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
        <description>Change in percent body fat as measured by DEXA scan at 6 months compared to randomization</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Body Fat From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery.</title>
          <description>Change in percent body fat as measured by DEXA scan at 6 months compared to randomization</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.82" lower_limit="-3.83" upper_limit="0.20"/>
                    <measurement group_id="O2" value="2.65" lower_limit="-1.21" upper_limit="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Systolic Blood Pressure From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery</title>
        <description>Change in systolic blood pressure at 6 months compared to baseline</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Systolic Blood Pressure From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery</title>
          <description>Change in systolic blood pressure at 6 months compared to baseline</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" lower_limit="-7.10" upper_limit="16.34"/>
                    <measurement group_id="O2" value="12.63" lower_limit="-5.02" upper_limit="30.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Lean Mass</title>
        <description>Change in percentage of lean body mass as measured by DEXA scan at 6 months compared to randomization</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Lean Mass</title>
          <description>Change in percentage of lean body mass as measured by DEXA scan at 6 months compared to randomization</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" lower_limit="-0.20" upper_limit="3.83"/>
                    <measurement group_id="O2" value="-2.65" lower_limit="-6.51" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Truncal Fat</title>
        <description>Change in percentage of truncal fat as measured by DEXA scan at 6 months compared to randomization</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Truncal Fat</title>
          <description>Change in percentage of truncal fat as measured by DEXA scan at 6 months compared to randomization</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.67" lower_limit="-5.19" upper_limit="-0.16"/>
                    <measurement group_id="O2" value="2.74" lower_limit="-0.14" upper_limit="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Android Fat</title>
        <description>Change in percentage of android fat as measured by DEXA scan at 6 months compared to randomization</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Android Fat</title>
          <description>Change in percentage of android fat as measured by DEXA scan at 6 months compared to randomization</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" lower_limit="-5.67" upper_limit="-0.32"/>
                    <measurement group_id="O2" value="3.33" lower_limit="0.23" upper_limit="6.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Gynoid Fat</title>
        <description>Change in percentage of gynoid fat as measured by DEXA scan at 6 months compared to randomization</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Gynoid Fat</title>
          <description>Change in percentage of gynoid fat as measured by DEXA scan at 6 months compared to randomization</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" lower_limit="-3.65" upper_limit="0.28"/>
                    <measurement group_id="O2" value="2.17" lower_limit="-2.26" upper_limit="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Spine Bone Mineral Density</title>
        <description>Change in spine bone marrow density as measured by DEXA scan at 6 months compared to randomization</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spine Bone Mineral Density</title>
          <description>Change in spine bone marrow density as measured by DEXA scan at 6 months compared to randomization</description>
          <units>grams per square centimeter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.07" upper_limit="0.03"/>
                    <measurement group_id="O2" value="0.14" lower_limit="-0.11" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leg Bone Mineral Density</title>
        <description>Change in leg bone marrow density as measured by DEXA scan at 6 months compared to randomization</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug (Canagliflozin)</title>
            <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leg Bone Mineral Density</title>
          <description>Change in leg bone marrow density as measured by DEXA scan at 6 months compared to randomization</description>
          <units>grams per square centimeter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.03" upper_limit="0.05"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.37" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over a period of 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Drug (Canagliflozin)</title>
          <description>Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
canagliflozin: encapsulated (gelatin capsule).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
Placebo (for canagliflozin): encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased hunger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Increased thirst</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Increased urination</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <description>Vertigo/Dizziness</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Genital yeast infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sangeeta Kashyap</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>(216) 445-2679</phone>
      <email>kashyas@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

